Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus ZYRTEC ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus ZYRTEC ALLERGY.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES vs ZYRTEC ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a peripheral H1-receptor antagonist that selectively inhibits histamine-mediated effects on H1 receptors, reducing allergic symptoms. It does not penetrate the blood-brain barrier significantly, minimizing sedation.
Selective peripheral histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
Adults and children 12 years and older: 180 mg orally once daily or 60 mg orally twice daily.
5–10 mg orally once daily; maximum dose 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–15 hours) in healthy adults. This supports once-daily dosing. Half-life may be prolonged in patients with renal impairment (up to 19 hours).
Terminal elimination half-life is approximately 8.3 hours (range 6–10 hours) in healthy adults, prolonged to 20–25 hours in patients with renal impairment (CrCl < 40 mL/min). No significant difference in elderly vs. young adults with normal renal function.
Fexofenadine is primarily excreted unchanged in feces (approximately 80%) via biliary elimination, with minimal renal excretion (approximately 11%). It is not metabolized by the liver.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; approximately 10% is excreted in feces via biliary route. Total renal excretion includes both parent drug and metabolites, with cetirizine largely unchanged.
Category A/B
Category C
Antihistamine
Antihistamine